 In the study, after evaluation of the general and physical status, eligible patients will be enrolled and randomly assigned into two arms at an 1:1 ratio. In the control arm patients will be receiving standard therapy according to National Comprehensive Cancer Network NCCN guide line control group and in experimental arm, patients will be receiving simultaneous standard therapy and injection of mix vaccine MV. MV will be injected weekly till disease progression. 